STOCK TITAN
  1. Home
  2. Sec-filings
  3. NBIX
  4. [Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity

[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Neurocrine Biosciences’ Chief Human Resources Officer Julie Cooke reported RSU vesting and tax withholding transactions. On January 31, 2026, 1,741 restricted stock units converted into the same number of common shares at $0 exercise price. To cover taxes, 997 shares of common stock were withheld at $136.06 per share, and no shares were sold on the market.

After these transactions, Cooke beneficially owned 27,602 shares of Neurocrine common stock, including 25,738 shares held by the Cooke Family Trust of 2004, over which she has voting and investment power. Each RSU represents the right to receive one share of common stock.

Positive

  • None.

Negative

  • None.
Insider Cooke Julie
Role Chief Human Resources Officer
Type Security Shares Price Value
Exercise Restricted Stock Unit 1,741 $0.00 --
Exercise Common Stock 1,741 $0.00 --
Tax Withholding Common Stock 997 $136.06 $136K
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 28,599 shares (Direct)
Footnotes (1)
  1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. 25,738 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 1,740 shares on January 31, 2023, vested as to 1,740 shares on January 31, 2024, vested as to 1,740 shares on January 31, 2025, and vested as to 1,741 shares on January 31, 2026, subject to the terms and conditions of the award.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cooke Julie
(Last) (First) (Middle)
6027 EDGEWOOD BEND CT.
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Human Resources Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/31/2026 M 1,741 A $0 28,599 D
Common Stock 01/31/2026 F 997(1) D $136.06 27,602(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (3) 01/31/2026 M 1,741 (4) (4) Common Stock 1,741 $0 0 D
Explanation of Responses:
1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
2. 25,738 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.
3. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
4. This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 1,740 shares on January 31, 2023, vested as to 1,740 shares on January 31, 2024, vested as to 1,740 shares on January 31, 2025, and vested as to 1,741 shares on January 31, 2026, subject to the terms and conditions of the award.
Remarks:
/s/ Darin Lippoldt, Attorney-in-Fact 02/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR